Portfolio

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The Company is based in Woburn, Massachusetts, with an R&D facility in Oxford, UK.

Their lead cancer program, OncoVEXGM-CSF, is a first in class oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed.

Industry :	Maladies infectieuses
Location :	Oxford, UK et Woburn, USA
Funds :	Innoven FCPI 2002, 2003. FCPI Poste Innovation 1, 2, 3, 5, 6.
Contact:	Jean-Sébastien Cleiftie

Aucun actualité en relation.